Published in J Virol on November 19, 2008
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
NF-kappaB serves as a cellular sensor of Kaposi's sarcoma-associated herpesvirus latency and negatively regulates K-Rta by antagonizing the RBP-Jkappa coactivator. J Virol (2009) 1.04
NF-κB as a target for oncogenic viruses. Curr Top Microbiol Immunol (2011) 0.86
Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv Virus Res (2014) 0.86
The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene. J Virol (2010) 0.83
The LMP1 promoter can be transactivated directly by NF-kappaB. J Virol (2009) 0.81
Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem (2011) 0.80
Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor. J Virol (2016) 0.78
Id1 interacts and stabilizes the Epstein-Barr virus latent membrane protein 1 (LMP1) in nasopharyngeal epithelial cells. PLoS One (2011) 0.78
NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma. J Virol (2016) 0.77
EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma. Oncotarget (2015) 0.77
Nuclear factor κB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells. World J Virol (2014) 0.75
Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells. J Virol (2017) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 13.46
A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst (1973) 10.64
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
High efficiency DNA-mediated transformation of primate cells. Science (1983) 8.09
Introduction to NF-kappaB: players, pathways, perspectives. Oncogene (2006) 7.78
Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J (2002) 4.83
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci U S A (1988) 3.97
Transcriptional regulation via the NF-kappaB signaling module. Oncogene (2006) 3.92
The mechanism of transcriptional synergy of an in vitro assembled interferon-beta enhanceosome. Mol Cell (1997) 2.94
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A (2007) 2.64
Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene (2006) 2.60
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med (1988) 2.52
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene (2006) 2.20
Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol (1993) 2.00
NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J (1999) 1.87
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology (1996) 1.66
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol (2006) 1.61
Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res (2003) 1.60
Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol (1995) 1.57
The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene (2007) 1.52
LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol (2007) 1.46
Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J Virol (2003) 1.42
Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol (2001) 1.39
PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J Gen Virol (1995) 1.36
The 5' flanking region of the gene for the Epstein-Barr virus-encoded nuclear antigen 2 contains a cell type specific cis-acting regulatory element that activates transcription in transfected B-cells. Nucleic Acids Res (1988) 1.35
The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood (2007) 1.32
KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J Exp Med (1993) 1.29
The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther (2006) 1.24
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat. J Virol (1995) 1.22
The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation. Oncogene (2000) 1.16
Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology (1995) 1.09
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. J Virol (1995) 1.09
EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood (2004) 1.01
Two factors, IRF1 and KBF1/NF-kappa B, cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus. C R Acad Sci III (1993) 1.00
Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression. J Virol (2000) 1.00
Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res (2000) 0.98
Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J Virol (2005) 0.98
Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J Virol (2006) 0.98
DNA affinity purification of Epstein-Barr virus OriP-binding proteins. Methods Mol Biol (2005) 0.95
Additive effect of Sp1 and Sp3 in regulation of the ED-L1E promoter of the EBV LMP 1 gene in human epithelial cells. Virology (1999) 0.95
Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation. Virus Genes (2007) 0.83
The Epstein-Barr virus oncoprotein LMP1 inhibits the activity of viral or cellular promoters without inducing cytostasis. Virology (2006) 0.83
Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Methods (2009) 1.87
Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res (2005) 1.84
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet (2002) 1.73
Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci U S A (2011) 1.27
Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics (2011) 1.23
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol (2005) 1.16
Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett (2002) 1.10
MODULAR ANALYTICS: A New Approach to Automation in the Clinical Laboratory. J Autom Methods Manag Chem (2005) 1.00
Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis (2013) 0.99
Functional interaction of nuclear factor y and sp1 is required for activation of the epstein-barr virus C promoter. J Virol (2003) 0.96
An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom (2012) 0.94
O-Mannose and O-N-acetyl galactosamine glycosylation of mammalian α-dystroglycan is conserved in a region-specific manner. Glycobiology (2012) 0.92
Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides. J Proteome Res (2014) 0.90
LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins. J Proteome Res (2013) 0.89
Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease. Dement Geriatr Cogn Disord (2004) 0.88
Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol (2007) 0.87
The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. Clin Chem (2003) 0.87
Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. Hum Reprod (2003) 0.86
E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein-Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions. J Gen Virol (2012) 0.86
Identification of intracellular proteins associated with the EBV-encoded nuclear antigen 5 using an efficient TAP procedure and FT-ICR mass spectrometry. J Proteome Res (2008) 0.85
No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res (2002) 0.84
Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol Med Rep (2011) 0.84
Activity of the LMP1 gene promoter in Epstein-Barr virus-transformed cell lines is modulated by sequence variations in the promoter-proximal CRE site. J Gen Virol (2007) 0.84
An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. J Proteome Res (2014) 0.83
The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene. J Virol (2010) 0.83
Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation. Virus Genes (2007) 0.83
Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem (2007) 0.82
Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat Disord (2010) 0.81
Epstein-Barr virus nuclear antigen 5 inhibits pre-mRNA cleavage and polyadenylation. Nucleic Acids Res (2002) 0.79
Influence of epigenetic modifications of the interleukin-10 promoter on IL10 gene expression. Eur J Oral Sci (2012) 0.78
Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. Int J Oncol (2004) 0.78
An inflammatory equine model demonstrates dynamic changes of immune response and cartilage matrix molecule degradation in vitro. Connect Tissue Res (2015) 0.77
Interleukin-10 genotypes of the -1087 single nucleotide polymorphism influence sp1 expression in periodontitis lesions. J Periodontol (2011) 0.77
The transcobalamin codon 259 polymorphism should be designated 776C>G, not 775G>C. Blood (2003) 0.76
The Epstein-Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. J Gen Virol (2002) 0.76
The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: a randomized placebo controlled study. Int J Mol Med (2004) 0.75
The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee. Lipids Health Dis (2004) 0.75
[The Medical Biobank--a unique resource for medical research]. Lakartidningen (2005) 0.75